Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVIVO-TaVec200 in Relapsed/Refractory Multiple Myeloma
NCT07294625Phase 1Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LVIVO-TaVec400 in multiple myeloma (MM), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Treatment-emergent Adverse Events at 2 years, Pharmacokinetics in peripheral blood at 2 years and 2 more. Started Dec 2025; status: recruiting.
02
Drugs
LVIVO-TaVec400
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07294625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294625.